After confirming that patients with untreated de novo AML who did not achieve CR with the "7 + 3′′ induction therapy expressed more of the Myc signature gene, we further investigated whether Myc gene expression differ between groups in the prospective cohort. The gene discussed is MYC; the disease is acute myeloid leukemia.